{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T03:31:21Z","timestamp":1762054281168,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Ministry of Health, Czech Republic\u2014Conceptual Development of Research Organization","award":["00209805","65269705","LM2018128","LM2018125","MUNI\/A\/1427\/2021"],"award-info":[{"award-number":["00209805","65269705","LM2018128","LM2018125","MUNI\/A\/1427\/2021"]}]},{"DOI":"10.13039\/501100001823","name":"the Ministry of Education, Youth and Sports, MEYS-Czech Clinical Research Infrastructure (CZECRIN)","doi-asserted-by":"publisher","award":["00209805","65269705","LM2018128","LM2018125","MUNI\/A\/1427\/2021"],"award-info":[{"award-number":["00209805","65269705","LM2018128","LM2018125","MUNI\/A\/1427\/2021"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"specific university research Project","doi-asserted-by":"publisher","award":["00209805","65269705","LM2018128","LM2018125","MUNI\/A\/1427\/2021"],"award-info":[{"award-number":["00209805","65269705","LM2018128","LM2018125","MUNI\/A\/1427\/2021"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an \u201coff-label\u201d option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, p = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course.<\/jats:p>","DOI":"10.3390\/curroncol29060330","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:22:39Z","timestamp":1654820559000},"page":"4138-4147","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)\u2014Exploring Its Possible Clinical Relevance in Cancer Patients"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6533-6822","authenticated-orcid":false,"given":"Michal","family":"Rihacek","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic"},{"name":"Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic"},{"name":"Department of Laboratory Medicine, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic"},{"name":"Department of Biochemistry, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-3504","authenticated-orcid":false,"given":"Iveta","family":"Selingerova","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic"},{"name":"Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Kocak","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, \u017dlut\u00fd kopec 7, 656 53 Brno, Czech Republic"},{"name":"Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, \u017dlut\u00fd kopec 7, 625 00 Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Kocakova","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, \u017dlut\u00fd kopec 7, 656 53 Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4728-785X","authenticated-orcid":false,"given":"Eva","family":"Rihackova","sequence":"additional","affiliation":[{"name":"Department of Internal Cardiology Medicine, Faculty of Medicine, University Hospital Brno and Masaryk University, Jihlavska 20, 625 00 Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0922-592X","authenticated-orcid":false,"given":"Dalibor","family":"Valik","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic"},{"name":"Department of Laboratory Medicine, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic"},{"name":"Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic"},{"name":"Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Sterba","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic"},{"name":"Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic"},{"name":"The International Clinical Research Centre of St. Anne\u2019s University Hospital in Brno, Pekarska 53, 656 91 Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","article-title":"Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: Sunitinib","volume":"21","author":"Mena","year":"2010","journal-title":"Anticancer Drugs"},{"key":"ref_2","first-page":"80","article-title":"Targeted therapy of metastatic renal cell carcinoma and treatment sequences: A current view","volume":"8","author":"Poprach","year":"2014","journal-title":"Onkologie"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40266-016-0390-1","article-title":"Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice","volume":"33","author":"Poprach","year":"2016","journal-title":"Drugs Aging"},{"key":"ref_4","first-page":"218","article-title":"Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours","volume":"116","author":"Kocakova","year":"2015","journal-title":"Bratisl. Lek. Listy"},{"key":"ref_5","first-page":"88","article-title":"Targeted therapy based treatment of gastrointestinal stromal tumors","volume":"9","author":"Bencsikova","year":"2015","journal-title":"Onkologie"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2021.06.015","article-title":"Immune-based combinations for the treatment of metastatic renal cell carcinoma: A meta-analysis of randomised clinical trials","volume":"154","author":"Massari","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11912-021-01140-9","article-title":"Combination Therapy in Renal Cell Carcinoma: The Best Choice for Every Patient?","volume":"23","author":"Rossi","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/pbc.21909","article-title":"Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib","volume":"52","author":"Janeway","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-11-0237","article-title":"Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A children\u2019s oncology group study","volume":"17","author":"Dubois","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00280-011-1798-2","article-title":"Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: A Children\u2019s Oncology Group study","volume":"69","author":"DuBois","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Krchniakova, M., Skoda, J., Neradil, J., Chlapek, P., and Veselska, R. (2020). Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093157"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","article-title":"A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients","volume":"15","author":"Houk","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00280-019-03814-5","article-title":"Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: Results from a phase I\/II trial","volume":"84","author":"Verschuur","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/annonc\/mdn626","article-title":"Pharmacokinetics of sunitinib in hemodialysis","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/FTD.0000000000000663","article-title":"Therapeutic Drug Monitoring of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Cell Carcinoma in Adults\u2014A Review","volume":"42","author":"Demlova","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejca.2015.12.019","article-title":"Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment","volume":"56","author":"Kloth","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_18","first-page":"5225","article-title":"Tyrosine kinase inhibitor-induced macrocytosis","volume":"29","author":"Schallier","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMc071867","article-title":"Macrocytosis due to treatment with sunitinib","volume":"357","author":"Billemont","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_20","first-page":"e4310","article-title":"A Case of Cobalamin Deficiency and Macrocytic Anemia Secondary to Sunitinib","volume":"11","author":"Reed","year":"2019","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/cncr.23711","article-title":"Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma","volume":"113","author":"Rini","year":"2008","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1002\/cam4.919","article-title":"Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma","volume":"5","author":"Bourlon","year":"2016","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3747\/co.v17i2.470","article-title":"Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma","volume":"17","author":"Price","year":"2010","journal-title":"Curr. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","article-title":"Inhibition of c-Kit by tyrosine kinase inhibitors","volume":"100","author":"Galanis","year":"2015","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1002\/sim.1545","article-title":"Estimating regression models with unknown break-points","volume":"22","author":"Muggeo","year":"2003","journal-title":"Stat. Med."},{"key":"ref_26","unstructured":"R Core Team (2022, March 01). R: A Language and Environment for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMc070920","article-title":"Macrocytosis and cobalamin deficiency in patients treated with sunitinib","volume":"356","author":"Gillessen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12032-016-0818-9","article-title":"Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma","volume":"33","author":"Kucharz","year":"2016","journal-title":"Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s10147-012-0497-2","article-title":"Sunitinib adverse events in metastatic renal cell carcinoma: A meta-analysis","volume":"18","author":"Ibrahim","year":"2013","journal-title":"Int. J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/6\/330\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:25:18Z","timestamp":1760138718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/6\/330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["curroncol29060330"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29060330","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}